Preliminary initiatives by the Critical Path Institute’s Primary Mitochondrial Diseases Task Force have demonstrated the feasibility of cross-registry data harmonization to accelerate drug development for primary mitochondrial diseases, according to a white paper published in the Orphanet Journal of Rare Diseases. The authors reported that aligning data dictionaries and distinguishing shared from distinct clinical domains provides a viable pathway to overcome persistent data fragmentation across independent registries.
Primary mitochondrial diseases carry an estimated minimum point prevalence of approximately 1 in 5,000 births worldwide, though exact prevalence figures vary depending on the specific geographical region and population evaluated. Researchers have identified more than 470 causative genes associated with primary mitochondrial diseases.
Despite the substantial prevalence and known genetic drivers, the vast majority of primary mitochondrial diseases continue to lack treatments approved by the Food and Drug Administration. While recent regulatory approvals for Barth syndrome and thymidine kinase 2 deficiency represent notable advances, patients with nearly all other mitochondrial conditions remain dependent on supportive and off-label interventions.
The white paper emphasizes that drug development has encountered repeated clinical trial failures driven by marked disease heterogeneity, small patient enrollment cohorts, and an absence of sensitive, disease-specific assessment tools. Traditional outcome measures have frequently proved inadequate in clinical studies, underscoring an urgent requirement for validated, patient-centered endpoints capable of capturing meaningful clinical changes.
Patient- and clinician-led registries have become essential resources for facilitating rapid participant enrollment and gathering detailed real-world data reflecting patient experiences. However, an evaluation of existing registry platforms revealed substantial misalignment in collected data elements alongside areas of operational overlap, creating significant barriers to cross-study comparability and aggregate analyses.
Established in January 2024 as an unprecedented collaborative effort, the task force aims to establish common data standards and leverage integrated datasets to support trial design and regulatory decision-making. The authors concluded that coordinated data harmonization and cross-sector collaboration are essential to advancing PMD drug development.
Subject of Research: Data harmonization and endpoint development in primary mitochondrial diseases
Article Title: Addressing data fragmentation and drug development barriers in primary mitochondrial diseases: the C-Path Primary Mitochondrial Diseases (PMD) Task Force approach to data harmonization, integration, and endpoint development
Article References: Betourne, A., Bhatnagar, R., Reynolds, E., Walls, R., Weissig, V., Martini-Drew, D., & Zilber, S. (2026). Addressing data fragmentation and drug development barriers in primary mitochondrial diseases: the C-Path Primary Mitochondrial Diseases (PMD) Task Force approach to data harmonization, integration, and endpoint development. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-026-04625-7
Image Credits: AI Generated
DOI: 10.1186/s13023-026-04625-7
Keywords: primary mitochondrial diseases, Critical Path Institute, PMD Task Force, data harmonization, data integration, endpoint development, data dictionaries, patient registries, clinician-led registries, Barth syndrome, thymidine kinase 2 deficiency, disease heterogeneity, real-world data, genotype-phenotype relationships, rare disease drug development, clinical trial design
News Source: Ophelia Keating. (November 18, 2026). Task Force Demonstrates Feasibility of Cross-Registry Data Harmonization for Mitochondrial Diseases. Scienmag.



